In this article, we explain a pharmacogenetics tactic which allows to selectively and reversibly inactivate LC neurons making use of Designer Receptors Exclusively Activated by Designer Medications (DREADD). We show the expression of your hM4Di DREADD could be restricted to noradrenergic LC neurons and that the level of LC inhibition may be modifie